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HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the
presentation and outcome in autoimmune hepatitis type-1
NMF van Gerven1,17, YS de Boer1,17, A Zwiers1,2, BJ Verwer1, JPH Drenth3, B van Hoek4, KJ van Erpecum5, U Beuers6, HR van Buuren7,
JW den Ouden8, RC Verdonk9,10, GH Koek11, JT Brouwer12, MMJ Guichelaar13, JM Vrolijk14, MJ Coenraad4, G Kraal2, CJJ Mulder1,
CMJ van Nieuwkerk1, E Bloemena15, HW Verspaget3, V Kumar16, A Zhernakova16, C Wijmenga16, L Franke16, G Bouma1,2 and The Dutch
Autoimmune Hepatitis Study Group18
The classical human leukocyte antigen (HLA)-DRB1*03:01 and HLA-DRB1*04:01 alleles are established autoimmune hepatitis (AIH)
risk alleles. To study the immune-modifying effect of these alleles, we imputed the genotypes from genome-wide association data
in 649 Dutch AIH type-1 patients. We therefore compared the international AIH group (IAIHG) diagnostic scores as well as the
underlying clinical characteristics between patients positive and negative for these HLA alleles. Seventy-five percent of the AIH
patients were HLA-DRB1*03:01/HLA-DRB1*04:01 positive. HLA-DRB1*03:01/HLA-DRB1*04:01-positive patients had a higher median
IAIHG score than HLA-DRB1*03:01/HLA-DRB1*04:01-negative patients (Po0.001). We did not observe associations between HLA alleles
and alanine transaminase levels (HLA-DRB1*03:01: P=0.2; HLA-DRB1*04:01; P=0.5); however, HLA-DRB1*03:01 was independently
associated with higher immunoglobulin G levels (P=0.04). The HLA-DRB1*04:01 allele was independently associated with presentation
at older age (P=0.03) and a female predominance (P=0.04). HLA-DRB1*03:01-positive patients received immunosuppressive
medication and liver transplantation. In conclusion, the HLA-DRB1*03:01 and HLA-DRB1*04:01 alleles are both independently
associated with the aggregate diagnostic IAIHG score in type-1 AIH patients, but are not essential for AIH development.
HLA-DRB1*03:01 is the strongest genetic modifier of disease severity in AIH.
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INTRODUCTION
Autoimmune hepatitis (AIH) is an uncommon autoimmune liver
disease of unknown etiology.1,2 The disease has a prevalence of
17–18.3 per 100 000 and is characterised by chronic destructive
inflammation within the liver parenchyma, elevated serum
immunoglobulin G levels and the presence of serum
autoantibodies.1–4 AIH type-1 is characterized by antinuclear
antibodies (ANA), smooth muscle antibodies (SMA) and soluble
liver antigen/liver pancreas antibodies, and occurs predominantly
in adult women, whereas the rare AIH type-2 occurs predomi-
nantly in children and is associated with liver kidney microsomal-1
antibodies.1,2 In up to 10% of patients, a clinical overlap is seen
with primary biliary cirrhosis (PBC) or primary sclerosing cholangi-
tis (PSC).5,6 Based on these clinical characteristics, the international
AIH group (IAIHG) developed two scoring systems as tools to aid
in the diagnosis of AIH.3,7 Several small gene association studies
associated the HLA class-II alleles HLA-DRB1*03:01 and HLA-
DRB1*04:01 at the HLA-DRB1 locus with AIH susceptibility, but
were unable to identify reliable associations outside the HLA
region.8–15 Despite a shared amino-acid motif in the binding
groove between these respective HLA proteins, the HLA-
DRB1*03:01 and HLA-DRB1*04:01 alleles were shown to have
contrasting associations with disease severity and outcome of
AIH.8,9,16 Collectively, these alleles share the HLA-DRB1 locus on
chromosome 6, which means that homozygosity for one allele is
mutually exclusive for the other allele. Through a hypothesis-free
genome-wide association study we established the strong
association of HLA-DRB1*03:01 and HLA-DRB1*04:01 alleles with
AIH type-1 susceptibility in addition to two non HLA loci in a large
cohort of Caucasian patients and controls.17 Using this patient
cohort, we here aimed to take these findings a step further and
refine the role and significance of HLA-DRB1*03:01 and HLA-
DRB1*04:01 alleles in the clinical presentation IAIHG score and
outcome of type-1 AIH in a large cohort of patients.
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The included AIH cohort consisted of 145 males and 504 (78%)
females with a mean age at diagnosis of 48 years (s.d. ± 18). The
median revised IAIHG diagnostic score was 18 (interquartile range:
15–20). Evidence for a clinical overlap syndrome with PBC (AIH-
PBC) and PSC (AIH-PSC) was found in 57 (9%) patients and 44 (7%)
patients, respectively.
HLA-DRB1*03:01, HLA-DRB1*04:01 and IAIHG score
The combined allele frequency of HLA-DRB1*03:01 (32%) and HLA-
DRB1*04:01 (15%) was less than half of the total number of the
HLA-DRB1 alleles in the cohort. However, a total of 75% (n= 484) of
AIH type-1 patients was positive for one or two of these alleles.
Forty-three (9%) of these patients were compound heterozygote
for HLA-DRB1*03:01 and HLA-DRB1*04:01. The 165 (25%) HLA-
DRB1*03:01 and HLA-DRB1*04:01-negative patients had signifi-
cantly lower median IAIHG scores than HLA-DRB1*03:01/HLA-
DRB1*04:01-positive patients (16.2 interquartile range: 12.9–19 vs
18.3 interquartile range: 15.6–20.8; Po0.001; Figure 1). All
characteristics are summarized in Table 1.
Association of HLA with clinical features
The HLA-DRB1*03:01 allele was associated with the IAIHG score at
diagnosis (P= 0.01) and showed an independent additive associa-
tion with an IAIHG score ⩾ 18 after correction for multiple testing
(PHolmo0.001; Table 2). The HLA-DRB1*03:01 allele showed an
additive association with earlier age of onset (P= 0.01) and male
gender (P= 0.01). However, when tested in a model together with
HLA-DRB1*04:01, this significance disappeared (PHolm = 0.4 and
PHolm = 0.4, respectively; Table 2). Median immunoglobulin G
levels, but not alanine transaminase levels, were associated with
the HLA-DRB1*03:01 allele (Po0.001 and P= 0.2, respectively).
Autoantibody positivity for ANA and SMA was equally distributed
among the HLA-DRB1*03:01 genotypes. HLA-DRB1*03:01-positive
AIH patients more often had one or more concomitant
autoimmune diseases than those without HLA-DRB1*03:01
(P= 0.03), but there was no difference between homo- and
heterozygotes (27 vs 27%). HLA-DRB1*03:01-positive patients less
often had manifestations of AIH-PBC overlap syndrome (P= 0.01).
However, after correction for multiple testing in a multivariate
regression model, both the presence of concomitant autoimmune
disease and PBC overlap syndrome were no longer statistically
significant (PHolm = 0.06 and PHolm = 0.3, respectively; Table 2). All
characteristics are summarized in Supplementary table 1.
The HLA-DRB1*04:01 allele was associated a with higher
IAIHG score at diagnosis (P= 0.01) and showed an independent
additive association with an IAIHG score ⩾ 18 (PHolm = 0.005;
Table 2). In contrast to HLA-DRB1*03:01, HLA-DRB1*04:01 was
independently associated with later onset of disease (PHolm =
0.004) and female predominance (PHolm = 0.005). No associations
of HLA-DRB1*04:01 genotypes with immunoglobulin G and alanine
transaminase levels were found. The frequencies of positivity for
ANA and SMA, as well as the presence of one or more
concomitant autoimmune diseases were similarly distributed
among the HLA-DRB1*04:01 genotypes. In addition, we could
not identify a significant relation between HLA-DRB1*04:01 and
the occurrence of AIH-PSC and AIH-PBC. All characteristics are
summarized in Supplementary table 2.
HLA-DRB1 genotypes and clinical course
Although HLA-DRB1*03:01 was not associated with cirrhosis
(P= 0.7), it showed an independent additive relation with fibrosis
at diagnosis (P= 0.02). However, this association did not remain
statistically significant after correction for multiple testing in a
multivariate regression model (odds ratio 1.4, 95% confidence
interval: 1.1–1.9, PHolm = 0.1; Table 2). Cirrhosis and fibrosis were
similarly distributed among the HLA-DRB1*04:01 genotypes.
Patients with the HLA-DRB1*03:01 allele were more likely to
receive medication for AIH (Po0.001) in contrast to the HLA-
DRB1*04:01 allele (Po0.001). However, in a multivariate
regression model incorporating both HLA-DRB1*03:01 and HLA-
DRB1*04:01, only HLA-DRB1*03:01 retained statistical significance
(PHolmo0.001; Table 2). Evidence of hepatocellular carcinoma was
only observed in three patients (0.5%), who all were HLA-
DRB1*03:01 negative. Liver transplantation had only been
performed in 12 patients (2%), and 4 additional patients (1%)
were on the waiting list. HLA-DRB1*03:01-positive patients under-
went a liver transplantation and were on the waiting list more
often than HLA-DRB1*03:01-negative patients (4% vs 1%, P= 0.02;
Supplementary table 1). In contrast, no patients with HLA-
DRB1*04:01 were on the waiting list or had undergone liver
transplantation (Supplementary table 2).
DISCUSSION
In this large multicenter study, we show that HLA-DRB1*03:01
and HLA-DRB1*04:01 alleles are independently associated with a
higher overall aggregate IAIHG score at diagnosis. Both alleles are
thus not only risk factors for AIH type-1, but also have a clear
relation to the separate clinical characteristics that define this
disease.
Exogenous antigens are primarily presented on HLA class-II
molecules by professional antigen-presenting cells to CD4 T-cells.
So-called molecular mimicry, in which an immune response is
mounted against a pathogenic exogenous antigen, which is
similar to an endogenous (self) antigen, has been suggested as a
plausible mechanism for the development autoimmune
disease.18–20 Previous studies showed that HLA-DRB1*03:01-
positive patients have more severe laboratory abnormalities.21
Although we observed a strong independent association of HLA-
DRB1*03:01 with higher serum levels of the adaptive immune
system serum marker immunoglobulin G, we did not identify
significant associations between the HLA alleles and alanine
transaminase levels. Similarly, HLA-DRB1*03:01 and HLA-
DRB1*04:01-negative patient were less likely to be ANA or SMA
antibody positive, but we did not identify a significant association
between the individual HLA-DRB1*03:01 and HLA-DRB1*04:01
genotypes and these autoantibodies. Associations between HLA
Figure 1. Median IAIHG diagnostic score for the HLA-DRB1 geno-
types. Bars represent median scores with interquartile range (IQR) of
the international autoimmune hepatitis group (IAIHG) diagnostic
score for the HLA-DRB1*03:01 and HLA-DRB1*04:01 genotypes.
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alleles and autoantibodies have mainly been described for
pathogenic antibodies, such as the association of myasthenia
gravis with HLA-DRB1*03:01 and the association of anti-
citrullinated protein antibodies (ACPA) with the shared epitopes
at the HLA-DRB1*01, HLA-DRB1*04 and HLA-DRB1*10 alleles in
rheumatoid arthritis.22–24 In addition, Ferucci et al.25 recently
reported that HLA-DRB1*03:01 and anti-dsDNA are associated in
Alaskan native AIH patients. Similarly, Ma et al.26 identified an
association between HLA-DRB*03:01 and the presence of soluble
liver antigen antibodies, which are in turn associated with disease
severity. In contrast, the ANA and SMA antibodies that classify
type-1 AIH are neither pathogenic nor organ-specific, and thus
may constitute an epiphenomenon in AIH. Our findings are
consistent with the findings by Czaja et al.8 reaffirming that ANA
and SMA are useful in the diagnosis of AIH type-1 but do not
represent a specific pathogenic process.
So far, the basis for the strong female predisposition to type-1
AIH remains unclear. Age-related differences in genetic suscept-
ibilities and clinical phenotypes are evident in white North
American and Northern European patients.27 In line with previous
studies, we found that the HLA-DRB1*04:01 allele is associated with
presentation at older age and is more often seen in female
patients.9,16,28 We did not find an independent association
between HLA-DRB1*03:01 and these traits. Our results thus
implicate HLA-DRB1*04:01 as an age-related risk factor for type-1
AIH in females. This suggests that change in hormone status
and increasing age may lead to the occurrence of antigens that
are effectively presented and induce an immune response by
HLA-DRB1*04:01 but not HLA-DRB1*03:01.
In a recent study by Liu et al.29 in a large cohort of PBC patients,
no association was found for the HLA-DRB1*03:01 and HLA-
DRB1*04:01 alleles investigated in this study. Accordingly, our data








IAIHG score median (IQR) 16.2 (12.9–19) 18.3 (15.6–20.8) 592 o0.001
Gender (female); n (%) 128 (78) 373 (77) 646 0.4
Age; year median (IQR) 45.8 (27.4–60.8) 45.6 (29.9–59) 614 0.9
ALT; IU l− 1 median (IQR) 260 (97–655) 349 (114–846) 572 0.08
IgG; g l− 1 median (IQR) 17.2 (13.8–25) 22.5 (17–31.2) 477 0.001
ALP; IU l− 1 median (range) 151 (113–227) 142 (98–226) 570 0.2
SMA pos; n (%) 65 (52) 233 (61) 508 0.04
ANA pos; n (%) 81 (60) 284 (70) 540 0.08
Fibrosis (biopsy); n (%) 76 (58) 260 (65) 530 0.07
Cirrhosis (biopsy); n (%) 19 (14) 43 (11) 520 0.17
Concomitant autoimmune disease; n (%) 22 (15) 119 (27) 612 0.002
PBC overlap; n (%) 22 (13) 35 (7) 649 0.02
PSC overlap; n (%) 9 (6) 35 (7) 649 0.3
HCC; n (%) 2 (1) 1 (0.2) 649 0.16
Liver transplantation; n (%) 3 (2) 9 (2) 649 0.6
Liver transplantation and waiting list; n (%) 3 (2) 13 (3) 649 0.4
Treatment naive; n (%) 51 (31) 72 (15) 604 o0.001
Abbreviations: ALP, Alkaline phosphatase; ANA, antinuclear antibodies; HCC, Hepatocellular carcinoma; IAIHG, international autoimmune hepatitis group; IgG,
immunoglobulin G; PBC, Primary biliary cirrhosis; PSC, Primary sclerosing cholangitis; SMA, smooth muscle antibodies; ALT, alanine transaminase.





Beta/OR 95%-CI P PHolm
b Univariate
P
Beta/OR 95%-CI P PHolm
b
IAIHG score 0.01 0.01
IAIHG score⩾ 18 0.08 1.7 1.3–2.2 o0.001 0.02 1.7 1.2–2.5 0.005
Agec 0.01 −1.8 0.1 0.4 0.01 4.6 0.004 0.03
Femaled 0.01 0.8 0.6–1.1 0.2 0.4 0.001 2.0 1.2–3.3 0.005 0.03
IgG o0.001 2.3 0.006 0.04 0.5 1.4 0.2 1
Concomitant autoimmune disease 0.01 1.5 1.1–2.0 0.009 0.06 0.8 1.3 0.9–2.0 0.2 1
PBC overlap 0.01 0.7 0.4–1.1 0.1 0.3 0.9 0.7 0.4–1.3 0.2 0.8
PSC overlap 0.2 1.2 0.7–1.9 0.6 0.6 0.4 0.9 0.4–2.0 0.8 1
Fibrosis (biopsy) 0.02 1.4 1.1–1.9 0.02 0.1 0.2 1.0 0.7–1.4 0.9 0.9
Treatment naive o0.001 0.5 0.3–0.7 o0.001 o0.001 o0.001 1.0 0.6–1.7 0.9 1
Liver transplantation and waiting liste 0.07 1.9 1.0–3.8 0.07 0.4 0.05 - - -
Abbreviations: CI, confidence interval; IAIHG, international autoimmune hepatitis group; IgG, immunoglobulin G; OR, odds ratio; PBC, Primary biliary cirrhosis.
aLogistic/linear regression with HLA-DRB1*03:01, HLA-DRB1*04:01, sex and age as covariates. bP-value after Holm-Bonferroni correction for multiple testing. cAge
not included in multivariate model. dSex not included in multivariate model. eHLA-DRB1*04:01 not included in multivariate model.
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suggest that HLA-DRB1*03:01-positive AIH patients are less likely
to have manifestations of an overlap syndrome with PBC.
However, some of the clinical traits investigated in this study,
including the presence of AIH-PBC and AIH-PSC overlap, only
constitute small groups in this HLA-DRB1*03:01 and HLA-
DRB1*04:01-enriched AIH study population. This may explain the
lack of association with HLA-DRB1*03:01 between AIH and AIH-PSC
patients, which in previous genetic studies was found to be a
strong susceptibility risk factor in PSC.29,30
In contrast to the study by Czaja et al.,8 we did not find a clear-cut
association of HLA-DRB1*04:01 with the presence of concomitant
autoimmune disease. Instead, we identified an independent
relation between HLA-DRB1*03:01 and the presence of one or more
concomitant autoimmune diseases. HLA-DRB1*03:01 also showed
an independent, additive relation with the presence of fibrosis at
clinical presentation, suggesting a gene-dosing effect with more
severe disease in homozygotes relative to heterozygotes. It should
be noted that these results did not remain significant after stringent
correction for multiple testing. However, HLA-DRB1*03:01-positive
AIH patients more often received immunosuppressive medication
and were more likely to need a liver transplantation.
Previous studies have shown that patients with HLA-DRB1*03:01
and/or HLA-DRB1*04:01 can have variable severity of disease and
treatment outcomes. AIH Patients with HLA-DRB1*03:01 and/or
HLA-DRB1*04:01 alleles had a greater frequency of treatment
failure during corticosteroid treatment, and HLA-DRB1*03:01
accounted for the observed association for poor outcome.8,16 In
our study, o3% of the included patients were either transplanted
or considered for liver transplantation, but none of these were
HLA-DRB1*04:01-positive. As these data were retrospectively
collected from the registries of all three liver transplant centers
in the Netherlands, it is unlikely that any cases were missed.
In this study, we found clear, independent associations between
the HLA-DRB1*03:01 and HLA-DRB1*04:01 alleles and the IAIHG
score. Given the strong relation of the HLA-DRB1*03:01 and HLA-
DRB1*04:01 alleles with overall disease susceptibility in the Dutch
population17 and the association with the primary end point, we
aimed to describe the effect of the HLA-DRB1*03:01 and HLA-
DRB1*04:01 alleles on the individual clinical variables in this cohort.
Although this is the largest investigated cohort to date, this study
has a relatively low power to identify associations with several
clinical traits when stringent correction for multiple testing is
applied. It should be noted that this study was performed in a
cohort of Caucasian type-1 AIH patients with mostly adult onset of
the disease, whereas several previous studies in different popula-
tions have identified HLA-DRB1*13:01, HLA-DRB1*04:04, HLA-
DRB1*04:05 and HLA-DRB1*07 as HLA susceptibility alleles for both
AIH type-1 and 2. These alleles were not found to be associated
with AIH type-1 in the Netherlands, which shows that the
susceptibility profile of AIH differs between populations and disease
phenotype. Despite this, our observations reaffirm the likelihood
that disease severity and treatment response in type-1 AIH have a
genetic basis and that it may be possible to define genetic indices
of prognosis. In clinical practice, the assessment of HLA-DRB1 alleles
can help to identify individuals who may have an unfavorable
prognosis. This study emphasizes the importance of genetic factors
in occurrence, clinical expression and behavior of AIH.
We conclude that the type-1 AIH risk alleles HLA-DRB1*03:01
and HLA-DRB1*04:01 are predictors of clinical presentation of type-




The cases for the discovery set were identified by the Dutch AIH Study
Group consortium (http://www.autoimmuunhepatitis.nl), as described
previously.17 Between 2008 and 2012, we recruited 743 patients with a
clinical diagnosis of AIH. Twenty-four patients with AIH type-2 were
excluded. An additional 70 patients were excluded owing to stringent
quality control measures, including control for population homogeneity.17,31
Prior to the start of the study, institutional review board approval to carry
out the study was obtained in all participating centers. All participants
provided written informed consent.
Data collection
AIH patients were identified by treating physicians and by searching the
database for international classification of diseases codes in eight
academic and 23 general hospitals in the Netherlands. The search was
performed in local diagnostic registers in the departments of gastroenter-
ology and hepatology as well as internal medicine. Clinical and
biochemical parameters were assessed in all patients to exclude other
etiologies such as alcoholic hepatitis, drug-induced liver disease and
metabolic disorders. Viral hepatitis was excluded by serological testing. If
performed, liver biopsy was used to establish diagnosis and presence of
fibrosis and cirrhosis. If available, we recorded manifestations of overlap
syndromes with PBC and PSC in the context of AIH as noted by the treating
physician. For PBC, these criteria consisted of antimitochondrial antibody
titers higher than 1:80 and typical histological findings, whereas
manifestations of PSC were recorded in case of typical histological and
radiological findings. The presence of other concomitant autoimmune
disorders, including type-1 diabetes mellitus, celiac disease, Hashimoto’s
disease, Sjögren syndrome, ulcerative colitis and Crohn’s disease, was
separately ascertained if noted in the medical records. Diagnostic scores
were determined according to the revised original IAIHG criteria.3 In this
study, results from HLA-DRB1*03:01 and HLA-DRB1*04:01 genotyping were
not incorporated in the IAIHG score. The median IAIHG scores between
HLA-DRB1*03:01/HLA-DRB1*04:01-positive patients and HLA-DRB1*03:01
and HLA-DRB1*04:01-negative patients was the primary end point of the
study. The clinical variables that constitute the IAIHG score as well as
outcome variables (Table 1) were selected as secondary end points for
further association analysis with the HLA-DRB1*03:01 and HLA-DRB1*04:01
alleles. Available data on induction and maintenance therapy, as initiated
and recorded by the treating physician, were retrospectively collected
from the patient hospital records. Similarly, both clinical response to
induction therapy and the occurrence of a relapse after treatment
withdrawal were scored as assessed by the treating physician. Liver-
related complications such as liver transplantation and/or the develop-
ment of a hepatocellular carcinoma were extracted from the records from
the eight academic centers.
Genotyping and quality control
Genomic DNA was obtained from peripheral blood mononuclear cells. The
genotyping, quality control and imputation of the MHC region in the AIH
samples is describes elsewhere.17 Briefly, cases were genotyped using the
Illumina CytoSNP 12.0 platform (containing 300 739 single-nucleotide
polymorphisms). Ethnic outliers and cases with a call rate of o99% were
excluded.31 After quality control, 649 AIH type-1 patients were included for
further analysis. Classic HLA genotypes were imputed using the SNP2HLA
imputation tool (http://www.broadinstitute.org/mpg/snp2hla/) on avail-
able single-nucleotide polymorphisms in the MHC region (20–40mb on
chromosome 6).32
Statistical analysis
Statistical analyses were performed using Statistical Package for Social
Sciences (SPSS 22.0, Armonk, NY, USA: IBM Corp.). Continuous variables
were described as means with their s.d. in case of Gaussian distribution or
median with interquartile range in cause of non-Gaussian distribution.
Summary statistics for categorical variables were expressed as numbers
with percentages. Depending on Gaussian or non-Gaussian distribution,
parametric (t-test and analysis of variance) and nonparametric (Mann–
Whitney U and Jonckheere-Terpstra) tests were used to test for statistical
significance of the differences between groups. Logarithmic transforma-
tion on continuous variables was applied when appropriate. We used Χ2-
or Fisher's exact test to compare proportional difference between groups.
Two-sided P-values o0.05 were considered statistically significant.
Significant associations between HLA alleles and the clinical and outcome
variables, were tested for independence in multivariate logistic or linear
regression model with the other investigated HLA-allele, age and sex as
forced selected covariates. We generated a dichotomous variable from the
ordinal IAIHG score with a cutoff at the overall median value (⩾18) to
HLA-DRB1*03:01 and HLA-DRB1*04:01 in AIH type-1
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perform multivariate analysis on this variable. Results with a P-value o0.05
after Holm–Bonferroni correction for multiple testing were considered
statistically significant.
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APPENDIX
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